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Equine degenerative myeloencephalopathy: 
prevalence, impact, and management
Erin N Burns
Carrie J Finno
Department of Population Health and 
Reproduction, School of Veterinary 
Medicine, University of California-
Davis, Davis, CA, USA
Abstract: Equine neuroaxonal dystrophy/equine degenerative myeloencephalopathy is an inher-
ited neurodegenerative disorder affecting many horse breeds. Clinical signs include a symmetric 
ataxia and an abnormal stance at rest, similar to cervical vertebral compressive myelopathy, 
equine protozoal myeloencephalitis, and equine herpesvirus 1 myeloencephalopathy. This review 
will provide an update on the disease prevalence, management, impact, and ongoing research.
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Introduction
Equine neuroaxonal dystrophy/equine degenerative myeloencephalopathy (eNAD/
EDM) is an inherited neurodegenerative disease characterized by the development 
of ataxia within the first year of life.1 Histologic hallmarks of eNAD/EDM include 
spheroids, axonal loss, and secondary demyelination within the caudal brainstem and 
spinal cord.1 eNAD and EDM are clinically indistinguishable,2 with EDM being a more 
advanced form of the disease. The histologic lesions in eNAD are confined to the cune-
ate and gracile nuclei of the caudal medulla oblongata, while in EDM, the lesions are 
more widespread and include demyelination within the ascending tracts of the spinal 
cord.2 Immunohistochemical calretinin staining has defined afferent proprioceptive 
tracts as the primary tracts damaged in eNAD/EDM horses, and isolated soma within 
the dorsal root ganglia as the source of dystrophic axons.3
While a genetic susceptibility to eNAD/EDM is highly suspected,5–9 the genetic 
basis of eNAD/EDM currently remains unknown. Previous studies in Quarter Horses,7 
Appaloosas,6 Morgans,9 and Standardbreds5 indicated an autosomal dominant and 
incompletely penetrant mode of inheritance.7 The disease has been reported in multiple 
breeds and a breed-specific susceptibility has not been identified.
The clinical signs of eNAD/EDM are an early onset of symmetric ataxia (≥ grade 
2/5),10 abnormal stance at rest, prominent hypermetria when walked with the head 
elevated, and general proprioceptive deficits.1,5,6,11–14 Some reports also detail additional 
neurologic symptoms including a decreased or absent menace response,1 lack of fight 
or flight response,1 and increased severity of ataxia in the pelvic limbs.15 Decreased 
serum α-tocopherol levels within the first 4 months of life have also been reported in 
some eNAD/EDM cases.1,16 In rare cases, eNAD/EDM has been reported concurrently 
with equine motor neuron disease.17
There are other neurological diseases which are clinically indistinguishable from 
eNAD/EDM. For example, horses affected with cervical vertebral compressive 
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myelopathy (CVCM), equine protozoal myeloencephalitis 
(EPM), or equine herpesvirus-1 myeloencephalopathy 
(EHM) demonstrate similar clinical signs as individuals 
with eNAD/EDM. EPM can be confirmed through antibody 
detection tests of cerebrospinal fluid and serum.18 EHM can 
be confirmed through virus culture of EHV-1 and molecular 
testing.19 A likely diagnosis of CVCM can be excluded based 
on standing cervical radiographs, myelography, or computed 
tomography. Cytological evaluation of cerebrospinal fluid 
does not typically reveal any abnormalities with CVCM or 
eNAD/EDM. Currently, the only way to definitively diagnose 
eNAD/EDM and CVCM is through postmortem histologic 
evaluation of the brainstem and spinal cord.
Vitamin E
Early studies of eNAD/EDM determined that foals raised on 
pasture incurred a protective effect against the development 
of the disease.20 It was hypothesized this protective effect 
was due to the increased consumption of vitamin E (vitE) 
as grazing pasture has a range of 45–400 IU vitE/kg of dry 
matter.21 This hypothesis was also supported in vitE supple-
mentation studies, demonstrating a decrease in disease inci-
dence within susceptible populations when supplemented.5 
The average 500 kg horse living on pasture would consume 
between 350 and 3,000 IUs of vitE/d when consuming 1.7% 
of their body weight in a 90% dry matter diet. This range is 
variable because the vitE available on pasture is subject to 
change based on the forage type available and the time of 
year.21 Serum α-tocopherol concentrations have been shown 
to fluctuate seasonally, with the highest concentrations 
identified between June and August, and the lowest between 
February and May.22
There are many different products on the market to 
supplement vitE into a horse’s diet. d-α-Tocopherol (RRR-
α-tocopherol) is the most bioactive isoform of vitE. All 
racemic vitE contains 2 different isoforms of vitE (d-α-
tocopherol and l-α-tocopherol). It is not recommended to 
supplement with all racemic vitE or synthetic vitE at any 
dose as it is not bioavailable.33 When supplementing with 
d-α-tocopherol (RRR-α-tocopherol), also called natural 
vitE, 10 IU/kg/d should be administered for a suspect eNAD/
EDM-affected horse.
Based on the authors’ clinical observations of eNAD/
EDM, we recommend 10 IU/kg/d of water-soluble natural 
vitE (RRR-α-tocopherol), totaling 5,000 IU/d for the aver-
age adult horse. This water soluble natural vitE is absorbed 
rapidly and therefore increases serum concentrations most 
efficiently.
The mechanism by which vitE protects a foal from disease 
development is currently not fully understood. It is known 
that d-α-tocopherol (RRR-α-tocopherol) is the most potent, 
bioavailable isoform of vitE,23 and that oxidative stress is 
occurring in the brainstem and spinal cord of eNAD/EDM 
affected horses.4,35 Current research is ongoing to determine 
the exact cause of this oxidative injury and how vitE prevents 
such damage.
Prevalence
There are many breeds affected by eNAD/EDM includ-
ing the Standardbred,5 Appaloosa,6 Morgan,9 Lusitano,24 
Paint,17 Thoroughbred,17 Arabian,25 Norwegian Fjord,26 and 
Quarter Horse.1,7,12,27,28 As a definitive diagnosis of eNAD/
EDM requires postmortem evaluation of the central nervous 
system, prevalence of the disease would more accurately be 
assessed with a genetic marker or biochemical assay. When 
diagnosing eNAD/EDM antemortem, it is imperative that 
the veterinarian rule out all other possible causes of the 
observed neurological deficits (CVCM, EPM, EHM, and 
trauma). α-Tocopherol supplementation may be indicated if 
the serum α-tocopherol levels are <2 µg/mL, and a history 
of neurological disease exists in related individuals.
A prospective study at Cornell University College 
of Veterinary Medicine found that EDM (n=23) was the 
second leading cause of equine spinal cord disease among 
all necropsied spinal cord disease cases between 1974 and 
1976.29 In this population of horses, EPM (n=32) was the 
leading cause of neurologic disease, with a total of 96 
horses evaluated. Eleven years later, a retrospective study 
of 19 ataxic horses was published by the University of 
Montreal College of Veterinary Medicine. In this study, 
CVCM was the leading cause of ataxia (n=11), and EDM 
was the second leading cause (n=4).30 In evaluating both 
these studies based on postmortem confirmed diagnoses 
of spinal ataxia, it can be concluded that CVCM, EPM, 
and eNAD/EDM account for the majority of spinal ataxia 
presentations in horses.
Since many neurologic horses are euthanized without 
postmortem evaluation, it is impossible to know the true 
prevalence of eNAD/EDM. The study of this disease is also 
complicated by the environments foals are raised in. If a 
susceptible foal is raised on pasture, they are less likely to 
demonstrate clinical signs of the disease,20 thus masking 
individuals who would have underlying predisposition for 
the disease. A 1990 study also found that application of 
insecticide, exposure to wood preservatives, and frequent 
time spent on dirt lots were risk factors for eNAD/EDM.20 
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Later epidemiological studies were able to confirm the risk 
associated with low vitE levels (ie, frequent time spent in 
dirt lots without access to pasture) but not the other factors.34
Case reports have demonstrated that eNAD/EDM affects 
horses globally. Equine NAD/EDM has been diagnosed in 
horses residing in New York,5,13,20 California,16 Nebraska,31 
Iowa,4 the United Kingdom,26 Italy,28 and Spain.25 Research-
ers have also studied eNAD/EDM in Iowa,4 Minnesota,3 
California,1,7,24,32 Oregon,6,11 and Florida.5 With this geo-
graphic distribution, we do not suspect there to be a specific 
geographic region in which eNAD/EDM cases are confined 
to, but for the number of cases to be increased in area where 
access to pasture is limited.
Impact
Any ataxic horse is not suitable for any riding purpose. 
Because eNAD/EDM is an inherited disorder, these individu-
als are also not suited for breeding. This causes an economic 
loss to the equine breeding and training industries.
The economic impact on the training and breeding 
industry can be estimated by the amount of money invested 
in the production of an affected horse. Although clini-
cal cases may present between 2 and 3 years of age,1 the 
disease typically develops within the first year of life.16,29 
The authors suspect this discrepancy to be caused by the 
increased workload, allowing owners and trainers to observe 
the lack of coordination that has existed since early in the 
animals’ life. As young horses enter a training regimen, 
they are continually asked to perform at increasingly higher 
levels. Affected horses would be unable to meet these expec-
tations, and subsequently be examined by a veterinarian for 
possible causes.
Long-term supplementation with 10 IU/kg/d is a financial 
burden on the breeding and training industry that must be 
considered when making breeding management decisions. 
The cost of supplementation for 1 genetically susceptible 
foal over the course of 2 years is nearly $3,500 (Table 1). 
Both the mare and the foal must be supplemented with this 
high dose of d-α-tocopherol (RRR-α-tocopherol) to achieve 
sufficient protective effects. As the current methods to deliver 
water-soluble d-α-tocopherol (RRR-α-tocopherol) require 
daily oral administration of the most bioavailable liquid 
supplement, the burden of time spent dosing several horses 
within a breeding or training program can be substantial.
Management
Once clinical signs of ataxia are apparent, α-tocopherol 
supplementation will not improve the neurologic deficits. 
Progression of the disease can be halted through supple-
mentation, but the general proprioceptive ataxia will remain. 
Clinical signs of the disease typically progress at varying 
rates until the horse reaches 2 years of age, at which time 
signs stabilize.
Currently the best management practice for prevention of 
eNAD/EDM is to maintain pregnant mares, foals, weanlings, 
yearlings, and 2-year-old horses on lush green pastures. This 
ensures adequate consumption of vitE to protect against neu-
rodegeneration in the developing central nervous system. If 
Table 1 Average cost of d-α-tocopherol (RRR-α-tocopherol) supplementation per affected foal
 Mass (kg) Time (days) Dose/day (mL) Total (mL) Total bottles Estimated cost 
(US$)
Gestational stage
Mare (pregnant) 600 120 12 1,440 6.10 $427.12
Mare (lactating) 550 180 11 1,980 8.39 $587.29
Mare total 14.49 $1,014.41
Age of foal
Foal (0–3 months) 50 90 1 90 0.38 $26.69
Foal (3–6 months) 150 90 3 270 1.14 $80.08
Weanling (0.5–1 year) 300 180 6 1,080 4.58 $320.34
Yearling (1–1.5 years) 400 180 8 1,440 6.10 $427.12
Yearling (1.5–2 years) 450 180 9 1,620 6.86 $480.51
2–3 years 500 360 10 3,600 15.25 $1,067.80
Foal total 34.32 $2,402.54
Grand total $3,416.95
Notes: In order to prevent the development of eNAD/EDM in genetically susceptible foals, the mare and foal must be supplemented with 10 IU/
kg/d of water soluble natural d-α-tocopherol (RRR-α-tocopherol) for an extended period of time. Estimated cost calculated using a 236 mL bottle of 
liquid natural vitamin E at a dose of 500 IU/mL at a cost of $70 a bottle.
Abbreviations: eNAD/EDM, equine neuroaxonal dystrophy/equine degenerative myeloencephalopathy.
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adequate pasture is not available, the best practices outlined 
in Figure 1 should be followed.
Based on neonatal development studies at UC Davis,16 and 
previous research, clinical signs may be observable as early 
as 1–2 months of age.6,17,20,29 To provide the best treatment, 
foals should have a neurologic exam at 1 and 6 months of 
age, and every 6 months thereafter until 2 years of age for 
early disease detection (Figure 1). Within the first 4 months 
of life, the serum α-tocopherol level of the foal should be 
assessed.16 This critical window is the only time in which a 
difference exists between foals that progressed with normal 
neurologic function and foals that developed eNAD/EDM 
(Figure 1) (reference range >2 µg/mL).16 Ideally, the serum 
α-tocopherol level should be evaluated within the first week 
of life, as the difference between the 2 groups has been shown 
to be the largest during this time.16
Serum α-tocopherol concentrations of the dam can also 
be an indicator of the need for supplementation during preg-
nancy and lactation.16 Supplementation is indicated when 
serum concentrations are below 2 µg/mL in a pregnant mare.16 
If eNAD/EDM is suspected in the foal, the dam and offspring 
should be supplemented at 10 IU/kg/d d-α-tocopherol (RRR-
α-tocopherol). Supplementation in the dam should begin 
at the start of the third trimester and end when the foal is 
weaned. The foal should be supplemented from birth to 3 
years of age (Figure 1).
Current work is under way to develop an antemortem 
genetic test for eNAD/EDM at UC Davis. A genetic test 
would allow breeders to make more informed decisions about 
their breeding and management practices, ie, not breeding-
susceptible individuals in a dry climate lacking adequate 
access to pasture. A test would also allow veterinarians to 
better diagnose the cause of clinically observed ataxia.
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